Parsortix-PC1

Parsortix® PC1 is an FDA-cleared clinical device that isolates and collects circulating tumor cells (CTCs) from whole blood—specifically for patients with metastatic breast cancer (MBC)—so they can be analyzed downstream. Using a size- and deformability-based microfluidic cassette, the system captures intact epithelial and mesenchymal CTCs (including clusters) for cytology, molecular testing (DNA/RNA/protein), enumeration, and even single-cell work. As a liquid biopsy, it enables repeat, minimally invasive sampling to track disease and inform individualized oncology care when tissue biopsy is risky, unavailable, or impractical.

Please Log In to access Product Datasheet ...

Key points / features

• Clinical purpose: Isolation and harvest of intact CTCs from blood for subsequent analysis in MBC patients.
  
  

• Technology: Microfluidic capture based on cell size and deformability—no labels/antibodies required.
  
  

• CTC breadth: Captures epithelial, mesenchymal, and hybrid phenotypes, as well as CTC clusters.
  
  

• Downstream flexibility: Supports cytology, DNA/RNA/protein assays, CTC enumeration, and single-cell analyses.
  
  

• Use case vs. tissue biopsy: Provides a non-invasive, repeatable alternative when tissue sampling is unsafe or inaccessible; useful for monitoring disease evolution over time.
  
  

• Clinical rationale: Aligns with oncology guidelines recognizing the role of liquid biopsy to support decision-making in MBC when tissue is limited.
  
  

• Outcome focus: Facilitates ongoing tumor profiling to help guide personalized treatment.